Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

• Published in: JTO clinical and research reports 2024-03, Vol.5 (3), p.100638-100638, Article 100638
• Main Authors: Vansteenkiste, Johan F., Naidoo, Jarushka, Faivre-Finn, Corinne, Özgüroğlu, Mustafa, Villegas, Augusto, Daniel, Davey, Murakami, Shuji, Hui, Rina, Lee, Ki Hyeong, Cho, Byoung Chul, Kubota, Kaoru, Broadhurst, Helen, Wadsworth, Catherine, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J.
• Format: Article
• Language: English
• Subjects: Durvalumab; Immunotherapy; Locally advanced NSCLC; Original; Pulmonary toxicity; Radiotherapy
• ISSN: 2666-3643; 2666-3643
• DOI: 10.1016/j.jtocrr.2024.100638

In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression after platinum-based concurrent chemoradiotherapy (cCRT). Pneumonitis or radiation pneumonitis (PRP) was common in both arms. We report exploratory analyses evaluating the association of symptomatic (grade ≥2) PRP (G2+PRP) with baseline factors and clinical outcomes. Patients with WHO performance status of 0 or 1 were randomized (2:1) to 12 months of durvalumab or placebo, 1 to 42 days after cCRT. Associations between baseline factors and on-study G2+PRP in durvalumab-treated patients were investigated using univariate and multivariate logistic regression. PFS and OS were analyzed using Cox proportional hazards models adjusted for time-dependent G2+PRP plus covariates for randomization stratification factors without and with additional baseline factors. On-study G2+PRP occurred in 94 of 475 (19.8%) and 33 of 234 patients (14.1%) on durvalumab and placebo, respectively (median follow-up, 25.2 mo); grade greater than or equal to 3 PRP was uncommon (4.6% and 4.7%, respectively). Time to onset and resolution of G2+PRP was similar with durvalumab and placebo. Univariate and multivariate analyses identified patients treated in Asia, those with stage IIIA disease, those with performance status of 1, and those who had not received induction chemotherapy as having a higher risk of G2+PRP. PFS and OS benefit favoring durvalumab versus placebo was maintained regardless of time-dependent G2+PRP. Factors associated with higher risk of G2+PRP with durvalumab after cCRT were identified. Clinical benefit was maintained regardless of on-study G2+PRP, suggesting the risk of this event should not deter the use of durvalumab in eligible patients with unresectable stage III NSCLC.